Invasive meningococcal disease (IMD) is endemic in Canada, and rates of disease fluctuate from year to year without any definite pattern. However, increased incidences have been noted every 10 or 15 years in the past. Since the last serogroup A epidemic in 1941, IMD due to serogroup A strains has become rare, and most IMD in Canada is now due to serogroups B, C, Y, and W-135 (7, 27) .
A major recent change in the epidemiology of IMD in Canada is the introduction of the new serogroup C clone of ET-15 Neisseria meningitidis (C:2a:P1.5,2) strains, which caused two waves of increased disease incidence throughout Canada in the last 15 years (2, 31) . The first wave of disease caused by this C:2a:P1.5,2 ET-15 clone occurred in the early 1990s. As a response to the outbreaks caused by this new clone, targeted vaccination campaigns using the polysaccharide vaccines were carried out in several provinces (Ontario, Québec, Prince Edward Island, and British Columbia) (8, 13, 28, 29) . In the province of Québec, a province-wide vaccination campaign was launched between December 1992 and March 1993 after initial vaccination of the target population did not curtail the spread of this clone in that province (8) . These vaccination campaigns had been very successful in reducing the amount of serogroup C meningococcal disease activity in Canada from 1994 to 1999 (7, 26) . The effectiveness and cost/benefit ratio of the provincewide immunization against serogroup C meningococci in Qué-bec have been analyzed and reported (8, 9) .
In 2000 and 2001, several provinces (British Columbia, Alberta, Manitoba, Ontario, and Québec) noted a resurgence in meningococcal disease activity due to serogroup C N. meningitidis. In Québec, the outbreak was due to a unique antigenic variant of the serogroup C ET-15 clone (32) . To combat the spread of disease due to this second wave of IMD, the province of Québec initially launched local immunization programs using the plain polysaccharide vaccine to target high school students in the Québec City area where the initial outbreaks occurred. However, when the outbreak spread to other regions and also affected younger age groups, the province decided to launch another mass immunization campaign, and this time the newly licensed serogroup C glycoconjugated vaccine (Menjugate; Chiron, Emeryville, California) was used. Starting in May to June 2001, the conjugate vaccine was offered to all residents age 2 months to 20 years, initially in the Québec City area, and beginning in the summer of 2001, the immunization was extended to the same age group of residents in other regions of the province (10) . The effectiveness of this glycoconjugate vaccine was reported to be 96.8% in reducing the number of cases of serogroup C meningococcal disease in Québec (10) . In Québec, IMD is a notifiable disease. Clinical and laboratory-confirmed cases are registered in a provincial notifiable disease database. Clinical isolates and culture-negative clinical specimens (for PCR diagnosis) must be submitted to the Laboratoire de Santé Publique du Québec (LSPQ) for further analysis and characterization. Between October 2004 and March 2005, local public health officials together with the LSPQ of the Institut Nationale de Santé Publique du Québec noticed a cluster of six IMD cases due to serogroup B meningococci in region 12 (Chaudière-Appalaches) and one documented contact case in adjacent region 03 (La Capitale Nationale, Québec City). This cluster of cases included four cases identified by PCR diagnosis (detection of N. meningitidis-specific and serogroup B-specific DNA in normally sterile body fluids of patients), and the others were culture-confirmed cases. The National Microbiology Laboratory (NML) of the Public Health Agency of Canada was contacted to conduct a laboratory investigation of the causative agent in this cluster of IMD cases. This cluster of cases around the Québec City area prompted us to carry out an in-depth investigation, and here we present a report of the laboratory findings, which suggest that an emerging clone of serogroup B meningococci, belonging to sequence type 269 (ST-269), has been causing IMD in the province of Québec since 2003.
MATERIALS AND METHODS
PCR diagnosis and direct sequencing of antigen genes from clinical specimens. Extraction of DNA from cerebrospinal fluid (CSF) was accomplished by adding 1 ml of DNAzol (Molecular Research Center, Inc., Cincinnati, Ohio) to 0.1 ml of CSF in the presence of 0.01 ml of polyacryl carrier (Molecular Research Center, Inc., Cincinnati, Ohio) designed for isolation of small amounts of DNA, according to the manufacturer's instructions. For extraction of DNA from EDTA-treated whole-blood specimens, the QIAamp DNA minikit was used (QIAGEN Inc., Mississauga, Ontario, Canada).
PCR primers and thermal cycling conditions for the amplification of the serogroup-specific polysialyltransferase siaD genes as well as the N. meningitidisspecific ctrA gene were described by Borrow et al. (4, 5, 14) . PCR products were confirmed by DNA hybridization using biotin labeled probes and digoxigenin-11-dUTP (Roche Diagnostic, Laval, Québec, Canada) in the PCR amplification step, followed by PCR-enzyme-linked immunosorbent assay (ELISA) as described by Borrow et al. (4, 5) .
Identification, serogrouping, and typing of meningococci. N. meningitidis was identified by biochemical tests, and serogrouping was determined by bacterial agglutination with rabbit serogrouping antisera at the LSPQ (19) . Serotyping and serosubtyping were done at the NML by whole-cell ELISA (1), using monoclonal antibodies from a commercial kit (Rijksinstituut voor Volksgezondheid en Milieu, National Institute of Public Health, Bilthoven, The Netherlands). Monoclonal antibodies to serotype antigen 17 and serosubtype antigen P1.19 were provided by the Walter Reed Army Institute of Research. For strains that gave either no agglutination or nonspecific agglutination with the serogrouping antisera, detection of the serogroup B-, C-, Y-, and W135-specific siaD genes was carried out by PCR (4, 5) . Multilocus sequence typing (MLST) was done according to method described by Maiden et al. (17) , and isolates were assigned to STs according to the Neisseria MLST website (http://pubmlst.org/neisseria). Sequencing of porB and porA genes, which determine the serotype and serosubtype antigens, respectively, was done following the protocol and nomenclature of Sacchi et al. (22, 23) . The PorA and PorB VR types were described according to the nomenclature of Sacchi (22, 23) as well as the nomenclature given in the N. meningitidis PorA variable-region (VR) database (http://neisseria.org/perl /agdbnet/agdbnet.pl?file ϭ poravr.xml) and the N. meningitidis PorB variableloop typing scheme (http://neisseria.org/nm/typing/porb/varloops.shtml). Pulsedfield gel electrophoresis (PFGE) of NheI restriction enzyme-digested meningococcal genomic DNA and data analysis of DNA fingerprints, including generation of dendrograms, were done as essentially described by Tyler and Tsang (34) , using the Bionumerics software version 3.5 (Applied Maths, Kortrijk, Belgium).
RESULTS

Laboratory investigation of outbreak specimens. Between October 2004 and March 2005
, seven epidemiologically related invasive meningococcal disease cases were identified in Qué-bec's adjacent regions 03 and 12. Three cases were culture positive for serogroup B N. meningitidis, while four cases were identified by PCR diagnosis based on detection of both N. meningitidis-specific ctrA and the serogroup B-specific siaD genes (Table 1) .
Conventional serotyping and serosubtyping with monoclonal antibodies failed to identify the serotype and serosubtype antigens in the three culture-positive serogroup B isolates, and they were reported to the LSPQ as B:NT:P1.-(serogroup B, nonserotypeable and nonserosubtypeable). In order to understand the serotype and serosubtype nature of the outbreak strain as well as to confirm that the PCR-diagnosed cases were For the three bacterial cultures obtained, porB gene sequencing and MLST were performed to gain further knowledge about the nature of the outbreak strain. Results of porB gene sequencing suggested that the three isolates belong to serotype 17 based on the PorB VR types identified (VR1 ϭ B, VR2 ϭ C, VR3 ϭ 7, and VR4 ϭ 14b, according to the nomenclature of Sacchi et al. [22] ). The equivalent PorB variable loops according to the nomenclature of the N. meningitidis PorB typing scheme were I.9, V.13, VI.9, and VII.12 (http: //neisseria.org/nm/typing/porb/varloops.shtml).
By MLST the three isolates were identified as ST-269, since they all had the following housekeeping gene alleles: abcZ, 4; adk, 10; aroE, 15; fumC, 9; gdh, 8; pdkc, 11; and pgm, 9) (http://pubmlst.org/neisseria).
Based on the porA and porB gene sequencing results, the outbreak strain is identified as serotype 17 with the serosubtype antigens of P1.19,15. The lack of reaction of the outbreak strain with the anti-P1.15 monoclonal antibody may be related to the fact that in the outbreak strain, mutations involving two nucleotides in the VR2 region of its porA gene had resulted in changes in the amino acid composition of its VR2 epitope. Testing of the outbreak strains isolated from the three cases confirmed that they all reacted with the monoclonal antibody to serotype 17 and with the monoclonal antibody to the serosubtype antigen P1. 19 . Prior to this study, monoclonal antibodies to the serotype antigen 17 and the serosubtype antigen P1.19 had not been used to characterize meningococcal strains in Canada, partly because these reagents were not commercially available. Fig. 1 . Those isolates typed as B:17:P1.19 have either identical or highly similar (90% or higher relatedness) DNA fingerprints, while those strains that showed no reaction to the serotype 17 and serosubtype P1.19 monoclonal antibodies show different PFGE patterns (60% or less relatedness).
Of the 38 IMD cases caused by the B:17:P1.19 strain, 19 (50%) were in males and 19 were in females (Table 3) . Their ages range from 20 months old (1.71 years) to 86 years old (median, 18 years). Approximately 45% (17 cases) of the patients were aged 10 to 19 years, 26% (10 cases) were 20 to 39 years, and 16% (6 cases) were 1 to 9 years. No patients were younger than 1 year old. Cases were located in 11 (61%) of the 18 regions of Québec, and 23 (61%) of the 38 patients lived in three adjacent regions. (Fig. 2) .
DISCUSSION
Serogroup B N. meningitidis is responsible for causing endemic disease in Canada and has been described as genetically heterogeneous (3), with no single clone or any particular antigenic type predominating among the invasive disease isolates. For example, during a survey of serogroup B isolates obtained from disease cases from 1994 to1996, 177 multilocus enzyme electrophoretic types (ETs) were identified among the 301 isolates, with most of the 136 ETs represented by single isolates. The most common clone or clonal complex is the ET-5 complex, and there were 36 isolates identified in this clone. All 36 isolates that belong to the ET-5 complex had either serotype antigen 1, 4, or 15. The other common ETs identified were ET-98 (with 18 isolates), ET-169 (16 isolates), and ET-134 (8 isolates). ET-98 isolates were either typed as serotype 14 and/or serosubtyped as P1.14. Thirteen of the 16 ET-169 isolates were typed as NT:P1.13. These data suggests that the ST-269 clone identified in this study and represented by the antigenic formula B:17:P1.19 is unrelated to these previously identified clones. We do not have further information on the ET-134 clone, but it did not appear to be isolated solely from one province, nor did it appear to have any unique antigens. Strains of N. meningitidis with the serotype antigen 17 are common in neither Brazil (21) nor the United States (20, 30) ; however, serogroup B strains with the serosubtype antigens P1.19 and 15 were commonly found in both the United States (24, 30) and Brazil (25) .
Serogroup B clones that have been described in the literature as causing epidemic disease include ET-5 (ST-32 complex), cluster A4 (ST-8 complex), and lineage III (ST-41/44 clonal complex) (6) . Although sporadic cases due to these three well-characterized serogroup B clones have been found in Canada, they do not appear to share any properties (housekeeping enzyme alleles or serotype/serosubtype antigens) with the ST-269 clone identified in this report. Also, no outbreaks due to these clones have been reported in Canada, with the exception of a spatio-temporal cluster of five IMD cases due to ET-5 serogroup B meningococci that occurred in 1995 on the Island of Montréal (16) . The occurrence of this cluster of cases coincided with the increase in the proportion of IMD due to Sixty-four percent of the isolates in the ST-269 clonal complex belong to serogroup B, 7% belong to serogroup C, and the rest are mostly either nongroupable or have serogroup information listed as unspecified. Slightly fewer than half of the isolates were recovered from carriers, and an equal number were from invasive disease cases, while the remaining small numbers were from unspecified sources. The earliest record of isolates belonging to the ST-269 clonal complex is from two invasive disease cases in The Netherlands in 1970, and both strains belonged to serogroup B. Also interesting is the recent report of an increase in the ST-269 clone among invasive disease isolates of N. meningitidis in Scotland, which may be related to the introduction of the meningococcal serogroup C polysaccharide conjugate vaccine in the United Kingdom in 2000 (11) .
In contrast to what has been described for endemic serogroup B meningococcal disease, which has the highest incidence in the age group of under 2 in Canada (12, 18) , IMD cases due to the current B:17:P1.19 strain affected mainly adolescents and young adults between the ages of 10 and 30 (25 out of 38 cases, or 65.8%). In more than half of the cases (22 cases, or 57.9%), the B:17:P1.19 isolates were obtained from CSF cultures, and in 16 cases (42.1%), the bacteria were isolated from blood cultures. Further clinical and epidemiological information on IMD cases caused by this emerging clone of serogroup B meningococci is pending and will subsequently be published.
Concurrent with the findings of an increase in the number of isolates belonging to the B:17:P1.19 ST-269 clone in Québec was the appearance of three serogroup C isolates (two isolated in 2003 and one in 2004) that were originally typed as C:NT: P1.-but were subsequently found to be C:17:P1.19. Two of these three isolates belong to ST-269, and the third isolate belongs to ST-1059, which is a member of the ST-269 complex.
Although it is very difficult to know for sure whether the B:17: P1.19 changed into C:17:P1.19 or vice versa, the following evidence suggests that the capsule switch took place from serogroup B to serogroup C. First, most serogroup C isolates from IMD cases in Canada belong to the ET-15 clonal type (15) , and serogroup C ST-269 isolates with the antigenic for- With the success in the control of serogroup C meningococci by using the conjugated serogroup C vaccine in Québec, it is important to examine whether mass vaccination against a single serogroup of meningococci would contribute to the emergence of a non-vaccine-preventable serogroup of meningococci, such as the potentially hypervirulent clone of ST-269 (B:17:P1.19). The only way to know is through enhanced surveillance of IMD by using both phenotypic and genotypic tools such as those described in this report.
